Narlumosbart compared with denosumab for multiple myeloma bone disease
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial compares a new drug called narlumosbart with denosumab (already used to treat bone problems) for people with multiple myeloma that has spread to the bone. The goal is to see if the new drug is as safe and effective at preventing bone complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have been newly diagnosed with active multiple myeloma.
- You must have at least one bone lesion that can be seen on imaging like X-ray, CT, MRI, or PET scan.
- You must be about to start your first line of anti-myeloma treatment, or have received less than one cycle (30 days) of it.
- You must have adequate organ function (liver, kidney, and calcium levels within specified limits).
- You must not have had previous treatment with denosumab or bisphosphonates, or have active dental or jaw problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
This trial compares two different combinations of medications for people with newly diagnosed multiple myeloma who are not planning to have a stem cell transplant. It looks at whether adding a targeted antibody drug is as effective as the standard approach.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.